<DOC>
	<DOCNO>NCT00038402</DOCNO>
	<brief_summary>The purpose study evaluate addition Herceptin standard chemotherapy treatment patient newly diagnose operable breast cancer . Other objective : 1 ) evaluate potential therapy reduce size tumor increase possibility breast conservative surgery , 2 ) evaluate ability regimen prevent recurrence breast cancer impact survival , 3 ) determine side effect profile addition Herceptin , 4 ) evaluate significance HER2 expression two different method .</brief_summary>
	<brief_title>Evaluation Addition Herceptin Standard Chemotherapy Neoadjuvant Setting Operable Breast Cancer</brief_title>
	<detailed_description>Participants receive Herceptin addition chemotherapy Taxol FEC . 'FEC ' Fluorouracil , Cyclophosphamide Epirubicin . During first course therapy Herceptin give day 1 needle vein 90 minute . Participants observe 1 hour harmful side effect . If none occur , later dose Herceptin give 30 minute instead 90 minute . On day 2 , participant give Taxol needle vein 24 hour . Participants receive drug Decadron ( dexamethasone ) , Benadryl ( diphenhydramine ) Tagamet ( cimetidine ) prior Taxol treatment prevent allergic reaction due Taxol . Participants observe 1 hour start Taxol harmful side effect . If none occur , Taxol Herceptin give day subsequent course . Taxol premedicated drug subsequent course . Participants receive Herceptin weekly 24 consecutive week . Taxol give participant every 3 week 4 course . Participants get fever infection treatment may give drug G-CSF . Granulocyte colony-stimulating factor ( G-CSF GCSF ) stimulate bone marrow make white blood cell , fight infection . After Taxol treatment , participant receive drug fluorouracil , cyclophosphamide , epirubicin ( FEC ) plastic tube vein . Fluorouracil give intravenously ( IV ) short infusion day 1 4 . Cyclophosphamide give intravenously short infusion day 1 . Epirubicin give IV day 1 . This FEC treatment repeat every 3 week total 4 treatment . Participants continue receive Herceptin weekly therapy FEC . After FEC treatment do surgery complete , patient tumor sensitive hormone begin take drug tamoxifen and/or aromatase inhibitor patient postmenopausal . The drug give pill day 5 year . Patients surgery remove part breast cancer . If sign lymph node armpit ( axilla ) contain cancer , lymph node remove . Patients may receive radiation treatment breast area armpit day six week . During study , participant blood test week first course treatment Taxol FEC . In subsequent course , blood test do prior administration chemotherapy . A mammogram sonogram obtain Taxol treatment FEC treatment . This help doctor keep track tumor size decide whether remove part breast nearby lymph node . After study , participant return checkup every 4 month year 1 2 , every 6 month year 3 , year . At visit , participant complete exam include blood test chest x-ray . Mammography do year . Before study , participant complete exam include blood test chest x-ray . A mammogram sonogram breast armpit obtain record tumor size . Small metal clip insert breast mark tumor tumor shrink rapidly response therapy ; way , tumor disappears drug treatment , surgeon still remove tissue around tumor . Sonography liver CT scan abdomen also do . In participant , 3-4 sample breast tumor take . The sample take use biopsy needle . An echocardiogram ( heart function test ) do every participant baseline . An echocardiogram do finish Taxol chemotherapy another one finishing FEC chemotherapy . Copies echocardiogram tape may send sponsor review . Women able child pregnancy test . After complete therapy , patient follow-up evaluation heart function ( baseline ) 4 month great last treatment . This investigational study . Taxol Herceptin drug use study approve U. S. Food Drug Administration . All patient treat MD Anderson Cancer Center outpatient clinic .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . All patient histologic confirmation invasive , noninflammatory carcinoma breast T23 ( great 2 cm ) , N01 , M0 eligible . Patients T1N1 ( histological confirmation nodal disease ) eligible study . 2 . Histologic confirmation invasive tumor do core needle biopsy . On tissue obtain , estrogen progesterone receptor ( ER/PR ) well Her2/neu ( determine immunohistochemistry ( IH ) and/or fluorescence situ hybridization ( FISH ) ) p53 do ( research evaluation ) . Tumor proliferation rate evaluable immunohistochemistry use paraffinembedded section monoclonal antibody ki67 . Residual tumor tissue save tissue bank future study . 3 . All patient Her2/neu positive eligible study . Her2/neu positivity protocol purpose determine IHC patient tumor 3+ FISH + eligible . 4 . Patients must sign informed consent indicate aware investigational nature study , keep institutional policy . 5 . All patient adequate bone marrow function , define peripheral granulocyte count &gt; 1,500/mm3 , platelet count &gt; 100,000 mm3 . Patients must adequate liver function , bilirubin within normal laboratory value . In addition , patient adequate renal function , define serum creatinine &lt; 2.0 mg % . 6 . Patients must normal cardiac ejection fraction determine baseline echocardiogram . Tape must save review central cardiologist . 7 . Patients underwent biopsy outside eligible measurable residual tumor . 8 . Patients multicentric disease extensive Ductal Carcinoma Situ ( DCIS ) eligible study . 9 . Patients history cardiac arrhythmia eligible study clear cardiology . 1 . Patients T1N0 disease eligible study . 2 . Those patient history invasive malignancy exclude except nonmelanoma skin cancer noninvasive cervical cancer . 3 . Patients history congestive heart failure exclude . 4 . Patients surgical therapy prior referral ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Non-Inflammatory Breast Cancer</keyword>
	<keyword>Operable Breast Cancer</keyword>
	<keyword>Herceptin</keyword>
	<keyword>Taxol</keyword>
	<keyword>FEC</keyword>
	<keyword>Fluorouracil</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Epirubicin</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Neosar</keyword>
</DOC>